Shares of VBI Vaccines, Inc. – (NASDAQ:VBIV) were down 2.3% on Thursday . The company traded as low as $3.72 and last traded at $3.74, with a volume of 77,524 shares changing hands. The stock had previously closed at $3.83.

The company has a 50 day moving average price of $3.99 and a 200-day moving average price of $4.00. The company’s market capitalization is $120.32 million.

A hedge fund recently bought a new stake in VBI Vaccines, Inc. – stock. Cambridge Investment Research Advisors Inc. bought a new position in shares of VBI Vaccines, Inc. – (NASDAQ:VBIV) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 1,433,100 shares of the biopharmaceutical company’s stock, valued at approximately $3,497,000. Cambridge Investment Research Advisors Inc. owned approximately 6.09% of VBI Vaccines, Inc. – as of its most recent SEC filing.

VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.